SECTION 2 510 (K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR § 807.92

Name:	Cameron Mahon, P. Eng. Director, Research and Development
Address:	XLTEK 2568 Bristol Circle Oakville, Ontario Canada L6H 5S1
Telephone:	(905) 829-5300
Fax:	(905) 829-5304
E-mail:	research@XLTEK.com
Common Names:	Evoked Potential Stimulator
Classification Name:	21 CFR § 882.1870 Stimulator, Electrical, Evoked Potential, 84 GWF, Class II
Predicate Devices:	XLTEK EP-16 [510(k) #K992313]
Description:	The XLTEK REAL PATIENT EP-16 is a 16 channel evoked potential stimulator which has embedded controls, is computer based, and can be used in conjunction with video and networking. The XLTEK REAL PATIENT EP-16 provides an option for the distribution of evoked potential data via a wired or wireless communication system using TCP/IP, Intranet, Internet, and physical means.

Substantial Equivalence:	The XLTEK REAL PATIENT EP-16 is substantially equivalent in terms of safety and effectiveness to the XLTEK EP-16 [510(k) #K992313]
Indications for Use:	The REAL PATIENT EP-16 is intended for use in the operating room and critical care areas for neurological monitoring and assessment. The instrument uses EEG, evoked potentials, and EMG techniques to provide the health professionals with information to help assess a patient's neurological status during surgery or long-term monitoring in the ICU. The XLTEK REAL PATIENT EP-16 is a 16 channel evoked potential stimulator which has embedded controls, is computer based, and can be used in conjunction with video and networking.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

MAR 1 9 2001

Mr. Cameron Mahon
Director, Research and Development
Excel Tech, Ltd.
2568 Bristol Circle
Oakville, Ontario
Canada L6H 5S1

Re: K010087
Trade Name: XLTEK Real Patient EP-16 Evoked Potential Headbox
Regulatory Class: II
Product Code: GWF
Dated: January 8, 2001
Received: January 11, 2001

Dear Mr. Mahon:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

for Miriam C Provost

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

ATTACHMENT 1 STATEMENT OF INDICATIONS FOR USE

Page __1__ of __1__

510(k) Number (if known) : K010087

Device Name : XLTEK REAL PATIENT EP-16 Evoked Potential Headbox
Indications for Use :

The REAL PATIENT EP-16 is intended for use in the operating room and critical care areas for neurological monitoring and assessment. The instrument uses EEG, evoked potentials, and EMG techniques to provide the health professionals with information to help assess a patient's neurological status during surgery or long term monitoring in the ICU.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provost
(Division Sign-Off)
Division of General, Restorative and Neurological Devices

510(k) Number K010087

Prescription Use ✓ OR Over-The Counter Use _____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)